PRF Technologies (PRFX) Non Operating Income (2020 - 2024)
PRF Technologies (PRFX) posted quarterly Non Operating Income of $33000.0 for Q2 2024, down 53.52% year-on-year from $71000.0 in Q3 2023, and down 44.07% on a QoQ basis from $59000.0 in Q1 2024.
PRF Technologies (PRFX) Non Operating Income (2020 - 2024) Analysis & Trends
PRF Technologies (PRFX) has reported Non Operating Income for 5 consecutive years, with $33000.0 the latest figure, recorded in Q2 2024.
- Quarterly Non Operating Income fell 53.52% year-over-year to $33000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $161000.0 (down 39.25% YoY) and the FY2025 annual result came in at $108000.0, up 16.13% from the prior year.
- Non Operating Income fell to $33000.0 in Q2 2024 per PRFX's latest filing, from $59000.0 in the prior quarter.
- Over the last five years, Non Operating Income for PRFX reached as high as $1.4 million in Q3 2023 and fell as low as -$1.3 million in Q4 2023.
- A 5-year average of -$43388.9 and a median of $6000.0 in 2021 frame the typical range for Non Operating Income.
- The largest YoY upside for Non Operating Income was 10776.92% in 2023 against a maximum downside of 1432.32% in 2023.
- Year by year, Non Operating Income stood at $897000.0 in 2020, then slumped by 98.44% to $14000.0 in 2021, then surged by 607.14% to $99000.0 in 2022, then plunged by 1432.32% to -$1.3 million in 2023, then soared by 102.5% to $33000.0 in 2024.
- According to Business Quant data, Non Operating Income over the past three periods registered $33000.0, $59000.0, and -$1.3 million for Q2 2024, Q1 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -7.50 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 33,000.00 |
| Mar 31, 2024 | 59,000.00 |
| Dec 31, 2023 | -1.32 Mn |
| Sep 30, 2023 | 1.39 Mn |
| Jun 30, 2023 | 71,000.00 |
| Mar 31, 2023 | 108,000.00 |
| Dec 31, 2022 | 99,000.00 |
| Sep 30, 2022 | -13,000.00 |
| Jun 30, 2022 | 22,000.00 |
| Mar 31, 2022 | -22,000.00 |
| Dec 31, 2021 | 14,000.00 |
| Sep 30, 2021 | -3,000.00 |
| Jun 30, 2021 | -41,000.00 |
| Mar 31, 2021 | -2,000.00 |
| Dec 31, 2020 | 897,000.00 |
| Sep 30, 2020 | -389,000.00 |
| Jun 30, 2020 | -519,000.00 |
| Mar 31, 2020 | -1.16 Mn |